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Enhanced Delivery of Neuroactive Drugs via Nasal Delivery
with a Self-Healing Supramolecular Gel
Julie Tzu-Wen Wang, Ana C. Rodrigo, Anna K. Patterson, Kirsten Hawkins,
Mazen M. S. Aly, Jia Sun, Khuloud T. Al Jamal,* and David K. Smith*
This paper reports the use of a self-assembling hydrogel as a delivery vehicle
for the Parkinson’s disease drug l-DOPA. Based on a two-component
combination of an l-glutamine amide derivative and benzaldehyde, this gel
has very soft rheological properties and self-healing characteristics. It is
demonstrated that the gel can be formulated to encapsulate l-DOPA. These
drug-loaded gels are characterized, and rapid release of the drug is obtained
from the gel network. This drug-loaded hydrogel has appropriate rheological
characteristics to be amenable for injection. This system is therefore tested as
a vehicle for nasal delivery of neurologically-active drugs—a drug delivery
strategy that can potentially avoid first pass liver metabolism and bypass the
blood–brain barrier, hence enhancing brain uptake. In vitro tests indicate that
the gel has biocompatibility with respect to nasal epithelial cells. Furthermore,
animal studies demonstrate that the nasal delivery of a gel loaded with
3H-labeled l-DOPA out-performed a simple intranasal l-DOPA solution. This
is attributed to longer residence times of the gel in the nasal cavity resulting in
increased blood and brain concentrations. It is demonstrated that the likely
routes of brain penetration of intranasally-delivered l-DOPA gel involve the
trigeminal and olfactory nerves connecting to other brain regions.
1. Introduction
Supramolecular gels are tunable and responsive soft materi-
als in which a “solid-like” network self-assembled from a low-
molecular-weight gelator (LMWG) immobilises a “liquid-like”
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phase.[1] They have wide-ranging potential
high-tech applications from environmen-
tal remediation to regenerative medicine.[2]
Gels based on LMWGs have particular po-
tential in the field of drug delivery as a result
of their ability to encapsulate active phar-
maceutical ingredients (APIs) within their
structures and control their release in a va-
riety of ways.[3] If the API is a part of, in-
teracts with, or is physically trapped within
the self-assembled “solid-like” LMWG net-
work, then its release can be relatively
slow, with gel erosion or triggered disas-
sembly being required to break down the
gel and release the API.[4] It is, however,
also possible that the API is only physi-
cally encapsulated within the gel, and is
thus freely dissolved in the mobile “liquid-
like” phase—in this case, API release can
be more rapid, with the gel acting primar-
ily as a formulation tool.[5] In terms of pa-
tient administration, gels are most often
considered for delivery by injection—for
example subcutaneously or intratumorally,
with the goal of controlled slow release.[6]
Topical and transdermal delivery by application of self-assembled
gels onto the skin is also of considerable interest,[7] often with the
goal of achieving effective delivery via non-invasive means and
avoiding first pass liver metabolism.
In recent years, nasal delivery has become an increasingly
interesting drug administration mode.[8] Nasal delivery has the
potential to achieve rapid systemic uptake via absorption into the
bloodstream through nasal epithelia.[9] Furthermore, the accessi-
bility of the olfactory and trigeminal nerves opens the possibility
of direct brain delivery without the need to cross the blood–brain
barrier.[10] With the rise in incidence of neurological diseases
associated with ageing, such as Parkinson’s and Alzheimer’s
diseases, the ability to achieve direct delivery of pharmaceutically-
active agents into the brain is of considerable importance.[11]
Taking Parkinson’s disease as an example, there are significant
difficulties with treatment.[12] The standard medication, based
on oral l-DOPA-carbidopa administration, is subjected to first
pass metabolism prior to uptake into the central nervous system,
resulting in very small amounts of the drug reaching the brain.
Furthermore, drug metabolism is up-regulated on prolonged
exposure to the drug, meaning that patients with this chronic
condition must progress to increasingly higher doses of the
drug, and ultimately receive the “rescue” pump-based direct
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delivery of l-DOPA-carbidopa intestinal gel into the jejunum
in an attempt to overcome some of the metabolic problems.[13]
Direct brain delivery of an active drug clearly has the potential to
be transformative for such patients.
In terms of achieving the best outcomes for nasal drug deliv-
ery, enhancing residence times in the nasal cavity, and improving
contact between the API and nasal epithelia or the olfactory nerve
are important and common strategies in enhancing the degree
of uptake, with modification of the dosage form (e.g., emulsion
formulations) or incorporation with mucoadhesive agents (e.g.,
pectin and chitosan polymers) in the formulation.[14] We rea-
soned that supramolecular gels could be ideally suited to this ap-
plication, given their potential for self-healing and self-assembly
in situ, combined with their soft rheological properties. Although
there has been rising interest in the use of responsive polymer
gels for nasal drug delivery,[15] perhaps surprisingly, in spite of
the attention focused on low-molecular-weight gelators,[3] they
have not previously been explored in this regard. There have been
isolated reports in which l-DOPA has been incorporated in dif-
ferent ways into supramolecular gels,[16] but these have not been
applied in a pharmaceutical setting.
With nasal delivery in mind, we reasoned that the ideal
supramolecular hydrogel would need shear thinning and recov-
ery capacity, so that it can be administered to the nose via in-
jection or spraying as a solution, and then form a thin gel film
in situ, coating nasal epithelia. Furthermore, the gel should be
based on simple components with low toxicity, and also have the
potential to easily degrade into non-self-assembling units, lim-
iting the risk of stable self-assembled structures building up in
vivo on long-term exposure to the delivery vehicle. Finally, the gel
should be compatible with neurologically-active drugs (we chose
in this study to focus on l-DOPA as a model drug) and be ca-
pable of rapid drug release. The goal is not to achieve slow re-
lease of the drug in the nasal cavity, or a permanent thin layer of
gel on the nasal epithelia. Indeed this would be both challenging
and undesirable asmucus is rapidly cleared from the nasal cavity,
meaning that in nasal drug delivery, a clearance half life of about
15min is typical.[17] As such, rapid release of the API from the gel
is important so that drug release kinetics do not become the lim-
iting factor in the overall delivery capacity of the system. In com-
parison to previously studied polymer gel systems, supramolec-
ular gels offer advantages of being fully reversible materials that
are easily modified synthetically, whilst retaining the potential to
be formulated with a wide range of additives that might poten-
tiate drug delivery and stability. This paper reports the results of
our initial studies, the development of a first generation LMWG
for this application, and through in vivo studies, demonstrates
the potential of supramolecular gels to enhance nasal residence
times and potentiate the delivery of APIs via this attractive mode
of administration.
2. Results and Discussion
Based on the design criteria above, we selected our recently
disclosed two-component gelation system (1) as a potentially
suitable LMWG .[18] This system assembles into gels when a
glutamine amide derivative and benzaldehyde are mixed to-
gether in a 1:1 ratio, with a reversible reaction between the two-
components giving rise to Schiff base 1, which is responsible
for self-assembly and gelation (Figure 1). We reasoned this gela-
tor was an ideal candidate for drug delivery applications as the
Schiff base should be non-persistent over long timescales in vivo
as a result of hydrolysis, potentially limiting the deposition of any
self-assembled material on repeated administration. This gelator
will break down into the glutamine amide derivative and ben-
zaldehyde. Benzaldehyde is generally regarded as safe,[19] being
used at concentrations up to 0.5% in some perfumes and also as
a flavoring.[20] Nasal irritation has been observed under extreme
conditions, on extended inhalation of volatilized benzaldehyde at
500 ppm for repeated 6 h periods.[21] However, it is rapidly me-
tabolized to benzoic acid and has very little acute toxicity.
We initially determined the amount of free benzaldehyde in
our two-component gel. Our standard gel was made by mix-
ing 3.5 mg of glutamine amide derivative and 1.15 mg (1.1 µL)
of benzaldehyde in 1 mL of water. This constitutes a benzalde-
hyde loading of 0.115% w/v, well below the concentration at
which benzaldehyde is used in (e.g.) perfumes. We then em-
ployed 1H NMR on the self-assembled gel in order to detect
the mobile components present within the liquid-like phase—
by using 1HNMR on gels, the self-assembled components of the
“solid-like” nanofibers are not detected, and only the solution-
phase mobile components are visualized (e.g., Figure S1a, Sup-
porting Information).[22] The use of a known mass of an inter-
nal standard (dimethylsulfoxide, DMSO), which is also mobile
in the liquid-like phase, therefore allows the quantification of any
non-assembled material. In this way, we were able to determine
that after gel assembly, ≈35% of the benzaldehyde was observed
as sharp NMR peaks, and hence could be assigned as being not
incorporated in the gel nanofibers. This therefore constitutes a
concentration of “free benzaldehyde” within the gel of 0.04% wt
vol−1 (400 ppm). 1HNMRstudies over time indicated that the free
benzaldehyde fell to ≈9% (0.01%, 100 ppm). It is also important
to note that this “free” benzaldehyde is in viscous aqueous solu-
tion and therefore is not strictly volatilized within the nasal cavity
and will not be problematic for rapid nasal delivery. We have also
previously shown that gels can still effectively be formed using
only 0.7 equiv. of benzaldehyde,[18] and using this approach, ef-
fectively all of the benzaldehyde is immobilized within the solid-
like gel nanofibers. We were therefore comfortable that this two-
component gel constituted a reasonable platform for further in-
vestigation as a nasal delivery system and that the impact of ben-
zaldehyde could be minimized.
This hydrogel was characterized in some detail in our previ-
ous report,[18] but it was important here to demonstrate that the
gel had suitable rheological properties to make it a candidate for
nasal delivery. Rheology was performed using a parallel plate ge-
ometry and as expected for a gel, G′ > G′′, demonstrating that
the solid-like characteristics dominate (Figure 2a). The frequency
sweep indicated that this gel was very soft indeed, with aG′ value
of just 85 Pa. Furthermore, the gel broke down at ≈12.5% strain,
and had a short linear viscoelastic region with the tendency to
behave like a viscous liquid. We reasoned that these properties
were suitable for potential nasal delivery, where a thin coating of
viscous material on the walls of the nasal cavity is required. It
has also previously been shown that softer gels can enhance skin
delivery compared with more rigid systems.[23]
Most importantly, for the delivery of a gel into the nasal cavity,
the gelmust rapidly assemble in situ after spraying or injecting in
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Figure 1. Synthesis of gelator 1 by mixing a glutamine amide derivative and benzaldehyde in water, structure of l-DOPA and advantages of the self-
assembling gelator approach for nasal delivery.
Figure 2. a,b) Rheological study of gel formed by compound 1 (0.46% w/v) in water showing a) response of storage and loss modulus (G′, blue and
G″, orange) to strain and b) the shear viscosity over time. At 200 s, a large strain is applied to the sample, which was then left to recover its gel-like
characteristics—this process took 40 s. c) (Left) SEM image of hydrogel formed from 1 loaded 1:1 with l-DOPA, (right) TEM image of hydrogel formed
from 1 loaded 1:1 with l-DOPA. d) Release of l-DOPA in vitro from the hydrogel formed by 1 loaded with l-DOPA (0.8 x 10–3m).
liquid form. We noted experimentally, that on injection through
a syringe, this gel initially exhibited shear thinning behavior and
acted as a solution, however, on standing after injection, a full
sample-spanning gel would once again form. This type of “self-
healing” capacity[24] would be a key requirement of a gel for nasal
delivery, as it will allow the gel to be applied to the nasal cavity, for
example via a nasal spray, and then reform a gel in situ to ensure
effective contact with the nasal epithelium. We therefore deter-
mined the shear thinning and recovery of this gel in more detail.
In particular, we were interested in the kinetics of this process to
ensure it had the potential to be pharmaceutically useful. Charac-
terization was achieved using rheological methods in which a gel
was formed on the plate and a shear force of 0.0126% applied at
a frequency of 2 Hz. After 200 s, the frequency was increased to
100 Hz for 30 s, leading to shear thinning and visible destruction
of the gel. The frequency was then lowered back to 2 Hz, and the
recovery of the gel was monitored over time (Figure 2b, Figure
S2, Supporting Information). Pleasingly, the gel recovered much
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of its rheological performance within≈10 s as indicated by the re-
covery of G′, the reformation of a soft gel-like material in which
G′>G′′ and the visible re-assembly of a gel on the rheometer.We
chose this methodology because spraying is typically performed
by application of high shear frequency,[25] and are therefore con-
fident that this gel has appropriate rheological properties for the
desired application.
We then went on to determine the ability of the gel to incor-
porate a model neurologically-active API. In this study, we chose
l-DOPA, which has the clinical need for improved Parkinson’s
treatment as described in the Introduction. In our standard for-
mulation, we loaded 3.5 mg of l-DOPA into the gel (1 mL of wa-
ter, 3.5 mg of glutamine amide derivative and 1.15 mg of ben-
zaldehyde). We could incorporate l-DOPA into the gel at load-
ings up to a 4:1 molar ratio with respect to the benzaldehyde and
form transparent gels (Table S1, Supporting Information). We
could still form gels at API loadings of 10:1, but not all of the l-
DOPA fully dissolved. In our standard formulation, the presence
of l-DOPA had minimal impact on gel performance. Rheologi-
cal studies indicated little change in the macroscopic behavior,
with G′ in the linear viscoelastic region being ≈100 Pa, and the
G′/G′′ crossover point being observed at 7% strain (Figures S3
and S4, Supporting Information). The l-DOPA-loaded gel still ex-
hibited thixotropic properties with rapid recovery to the gel phase
after application of high frequency shear. Scanning electron mi-
croscopy (SEM) and transmission electron microscopy (TEM)
imaging indicated minimal perturbation of the self-assembled
nanofibrillar network (Figure 2c and Figure S5, Supporting Infor-
mation). However, TEM imaging at higher l-DOPA loadings in-
dicated that aggregates associated with l-DOPA could also be ob-
served using this technique, consistent with the non-transparent
nature of these gels (Figure S6, Supporting Information).
1H NMR spectroscopy on samples of the gels loaded with l-
DOPA was used to provide some insight into the way l-DOPA is
incorporated into the gel. There are several possibilities for active
agents that have been formulated into supramolecular gels and
these can be distinguished via standard solution-phase 1H NMR
methods applied to a sample of gel:
i) The active agent can interact with the “solid-like” gel
nanofibers, or be entrapped within the gel network as a re-
sult of its size. In either case, the molecular-scale mobility of
the active agent is restricted, meaning it cannot be observed
by 1H NMR spectroscopy.
ii) The active agent can be dissolved within the “liquid-like”
phase of the gel, freely able to diffuse through the gel net-
work. In this case, the active agent can be detected by 1H
NMR in the same way as any dissolved solute.
iii) The active agent can react with the self-assembled fibers and
hence become immobilized in the gel, or lead to disassembly
of the material—this was considered possible in this case,
as l-DOPA contains an amine group which could plausibly
react with benzaldehyde, although it was considered unlikely
under the loading pH conditions.
Adding an internal standard to the gel allows us to quantify the
amount of “mobile” active agent, and hence gain effective insight
into themolecular-scale organization of the gel.[22] We found that
92% of the l-DOPA was visible in unmodified form via 1HNMR
spectroscopy as sharp peaks, quantified using a DMSO internal
standard, hence indicating that the active agent is essentially free
to diffuse through the gel, and does not significantly interact or
react with components of the “solid-like” self-assembled network
(e.g., Figure S1b, Supporting Information). Although this would
be a drawback for applications requiring controlled or slow re-
lease (and is something we are currently pursuing in that regard),
it is ideal for the proposed nasal deliverymode, as rapid release of
the unmodified active ingredient once the gel comes into contact
with the nasal epithelium is needed.
We went on to quantify the ability of the gel to release l-DOPA
in vitro. This was achieved by exposing the gel to a supernatant
receiving solution at pH 7, and taking aliquots from this super-
natant to determine the extent of release via UV–vis spectroscopy.
Performance was benchmarked against control gels, in which
l-DOPA was not present. Release of l-DOPA was rapid (Fig-
ure 2d), consistent with the view described above that l-DOPA
does not interact with the “solid-like” gel nanofibers, but instead
is highly mobile within the “liquid-like” environment of the self-
assembled gel. Not all of the l-DOPA was released from the gel,
and this may indicate that some of the l-DOPA under these con-
ditions is precipitated in the gel. We anticipate more l-DOPA
would have been released if the supernatant had been replaced
with fresh solution, but this is less relevant for rapid nasal deliv-
ery. The pattern of rapid release of more than 60% API is suit-
able for the proposed nasal delivery administration mode. We
also tested the stability of the gels in the presence of various rele-
vant additives to aqueous solution (Tables S2 and S3, Supporting
Information).
With nasal delivery inmind, we determined experimentally the
cytotoxicity of these self-assembled gels. This was achieved by ex-
posing nasal epithelial cells to the gels in vitro. A gel loaded with
4.8 x 10–3 m l-DOPA was formulated and human nasal septum
tumour RPMI 2650 cells were incubated with culture medium
containing 1%, 2%, 5%, and 10% gels (v/v) for 24 and 48 h. Cells
were treated with l-DOPA solution prepared in water at the same
range of l-DOPA concentration for comparison. As shown in Fig-
ure 3a, some concentration-dependent cytotoxicity was observed
in cells treated with l-DOPA-loaded gel for 24 h and 48 h (red
solid and dash lines). In contrast, no obvious toxicity was ob-
served in the cells treated with equivalent concentrations of l-
DOPA solution for 24 h and the cell viability only decreased at
the highest concentration at 48 h (green solid and dash lines).
The results indicated the toxicity was associated mainly with the
gel. We suggest this is most likely due to the presence of glu-
tamine amide units disassembled in culture medium and acting
as an amphiphile. Complete gel disassembly, however, is an ex-
treme scenario which may not take place, or only occur slowly,
upon in vivo nasal administration as the nasal cavity is covered
by viscous but not fluid mucus, and the timescales of exposure
are very much smaller (minutes rather than hours).
We further investigated the toxicity of the amphiphilic glu-
tamine amide by comparing it against other surfactants such as
Tween 80, a known “biologically-safe” surfactant that has been
used widely in food, cosmetics, and drug formulations,[26] and
cetyltrimethylammonium bromide (CTAB), a highly toxic but
common surfactant used as a surface coating agent.[27] Cells were
treated with plain gel without l-DOPA at equivalent loadings (up
to 0.35 mg mL−1). It should be noted that Tween 80 has a much
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Figure 3. Cytotoxicity of hydrogel and l-DOPA loaded hydrogel in human
nasal septum tumour RPMI 2650 cells. a) Cells were incubatedwith culture
medium containing up to 10% l-DOPA loading gel and l-DOPA solution
at the equivalent concentrations (up to 480 x 10–6m) for 24 and 48 h. b)
Cells were treated with various concentration of hydrogel, Tween 80 and
CTAB (up to 0.35 mg mL−1) for 24 and 48 h. Data are expressed as mean
± SD, n = 5. Cytotoxicity was assessed by the standard MTT assay.
higher molecular weight than the other two surfactants, and a
loading of 0.35mgmL−1 is actually equivalent in terms of concen-
tration to a gelator loading of 0.07 mg mL−1 (both ≈400 x 10–6 m
concentration). It was found that the disassembled gel was non-
toxic at low loadings (≈0.07 mg mL−1), comparable to Tween 80
at the same concentration, whereas severe toxicity was induced
by CTAB at much lower concentrations (Figure 3b). The results
therefore indicate some in vitro biocompatibility of the studied
gel.
To demonstrate the potential application of gels such as these
for intranasal drug delivery, we performed in vivo studies using
radiolabeled [3H]l-DOPA and studied the uptake and biodistribu-
tion of [3H]l-DOPA hydrogel following intranasal administration
in naïve Balb/c mice. Comparative studies were also performed
to dose mice with [3H]l-DOPA solution intranasally. Mice were
anaesthetized and injected with [3H]l-DOPA hydrogel or solu-
tion (l-DOPA 0.95 mg kg−1, 1.5 µCi per mouse). At defined time-
points (10 min, 20 min, 1 h; n = 3 for each timepoint), major
organs, brain tissue, and nasal cavity were excised following tran-
scardiac perfusion with saline under terminal anesthesia to avoid
false positive results from blood. Blood was collected at each time
point before perfusion.
The [3H]l-DOPA levels detected in brain, nasal cavity, and
blood following intranasal administration are shown in Figure
4. Overall organ biodistribution profiles of each delivery mode is
shown in Figure S7, Supporting Information. In view of brain
uptake, intranasal delivery of l-DOPA with the hydrogel for-
mulation appeared to be more effective (0.49±0.32% ID (in-
Figure 4. Uptake of [3H]l-DOPA formulated in hydrogel or in solution in
a) brain, b) nasal cavity, c) blood, and d) liver up to 1 h post intranasal ad-
ministration. At the experimental end points, whole body perfusion with
0.9% saline was performed and studied tissues were harvested and pro-
ceeded for liquid scintillation counting. Results are expressed as %ID per
tissue. Data are expressed as mean ± SD, n = 3. Statistical significance
is indicated in comparison between each mode at the same time-point.
*p < 0.05, **0.01 < p < 0.05; ***p < 0.01 (one-way ANOVA).
jected dose) after 10 min) than that observed in simple solu-
tion (0.16±0.08% ID after 10 min), suggesting potential bene-
fits of the gel formulation, presumably due to enhancing resi-
dence times in the nose for more effective uptake through nasal
epithelia (Figure 4a). Specifically, in support of this hypothesis,
27.55±3.73% ID of l-DOPA was found in the nasal cavity after
10 min (and 15.70±4.7% ID after 20 min) in the presence of
the gel, whereas this falls significantly to just 14.60±3.17% ID
after 10 min (and 6.44±2.54% ID after 20 min) when l-DOPA
was delivered as a solution (Figure 4b). The rapid brain adsorp-
tion of l-DOPA when applied intranasally (i.e., within half an
hour) has been reported[28] and is characteristic for intranasal ad-
ministration. In addition to the direct nose-to-brain route, drugs
could also be absorbed indirectly through the blood–brain path-
way since the nasal cavity is extensively vascularized. Pharma-
cokinetic profiles of l-DOPA in brain run parallel to those in
blood after nasal administration in both gel and solution forms
(Figure 4a,c). Interestingly, in addition to the significantly en-
hanced residence in the nasal cavity, there was also a significantly
higher level of l-DOPA in blood at the earliest time point when
the gel was present in the intranasal formulation. This is likely
also a result of increased retention time in the nasal cavity in the
presence of the gel. It is worth noting that the relatively rapid de-
cay of l-DOPA levels in the brain over the first hour after delivery
is mirrored by data found in other studies of intranasal delivery,
where, for example the period of peak l-DOPA concentration was
found to be 9–15 min after administration.[28a]
The intranasal route can ideally bypass first-pass metabolism
in the liver and gastrointestinal (GI) tract, which is the cause of
low bioavailability after oral administration, the current standard
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l-DOPA treatment. However, GI absorption and metabolism af-
ter nasal administration cannot be completely avoided as a por-
tion of drugsmight be either cleared into theGI tract by ciliamov-
ing towards the nasopharynx or be swallowed.[29] We observed
that the presence of the gel in the delivery formulation signifi-
cantly lowered the amount of l-DOPA found in the liver, particu-
larly at 20 min post administration (Figure 4d). We suggest that
when l-DOPA was injected intranasally as a solution, some of it
might be drained to the nasopharynx, ending up in the GI tract
and then undergoing the usual route of oral delivery, leading to
liver accumulation. We argue that the presence of the gelator has
the desired effect of viscosifying the overall formulation in the
nasal cavity, hence limiting the flow into the GI tract and prevent-
ing drainage to the nasopharynx. This argument is supported by
the observation that significantlymore l-DOPAwas foundwithin
the nasal cavity, and that its persistence there was significantly
longer if the gelator is present during intranasal delivery.
We also compared intranasal delivery of l-DOPA hydrogel
with intravenous injection of l-DOPA solution, which is some-
times prescribed to late-stage Parkinson’s patients who cannot
tolerate oral medications. Pleasingly, the results showed that
the nasal delivery of gel formulation achieved higher levels
in brain (0.49±0.32% ID versus 0.12 ± 0.01% ID) and blood
(0.79±0.11% ID versus 0.37±0.24% ID), and significantly lower
uptake in the liver compared with intravenous delivery of l-
DOPA at 10 min post administration (Figure S8, Supporting
Information). Higher levels of l-DOPA detected in liver follow-
ing intravenous injection are expected as a result of considerable
metabolism at the peripheral sites[30] and our results indicate
that this complication can be overcome by intranasal delivery at
ease. Nasal delivery with our gel formulation therefore achieves
4.1 times more brain uptake of l-DOPA and 2.1 times more
l-DOPA in the blood 10 min after administration than intra-
venous delivery of an equivalent dose. In this study, we did not
carry out comparative studies of oral l-DOPA delivery, however,
other published work[28a] indicates that IV delivery achieves
>10 times the effective concentration in both brain and plasma
compared to the oral delivery route. We therefore conclude that
our nasal delivery gels would be significantly more effective than
oral l-DOPA delivery.
It is worth reflecting further on the therapeutic rele-
vance of these observations. In a detailed pharmacokinetic
study comparing intranasal (2.5 mg kg−1 dissolved in maleic
acid/hydroxypropyl-𝛽-cyclodextrin/triethanolamine at pH 2.7)
and oral (80 mg kg−1, dissolved in saline) delivery of l-DOPA
in rats, it was demonstrated that levels of l-DOPA in the brain
achieved by intranasal delivery were 2.1 to 2.5 times higher than
oral delivery even though the dose was 32 times lower.[28a] In
a therapeutic efficacy study, l-DOPA applied nasally at a rela-
tively high dose of 12 mg kg−1 with the help of oil, improved
motor functions and performance in the rotation test using a
hemiparkinsonian rat model.[28b] In an alternative study using
the same hemiparkinsonian rat model, however, a much lower
dose of just 0.35 mg kg−1 delivered intranasally appeared to be
therapeutically effective in the forelimb placing task test 30 min
after administration.[31] This dosing regime was applied once a
day, and the therapeutic effects persisted until treatment was
withdrawn. This study therefore suggests the dose given here
of 0.95 mg kg−1 l-DOPA to mice (equivalent to 0.475 mg kg−1
to rats) does have the potential to be therapeutically effective.
Furthermore, there remains scope within our gel delivery sys-
tem to further increase the dose of l-DOPA—this preliminary
study was primarily aiming to show the benefits of our gel for-
mulation over simple intranasal administration of a solution—
the dose and therapeutic effects have not as yet been optimized.
In addition, it would be also desirable to optimize our system by
including carbidopa (a decarboxylation inhibitor) and/or other
delivery vehicles in the gel formulation, which can enhance l-
DOPA half life in the brain and significantly improve therapeutic
outcomes[28a,31]—work in this regard is ongoing.
We next performed a pilot study to investigate the transport
pathways of l-DOPA hydrogel in the brain after nasal administra-
tion. We determined the levels of radioactivity in different brain
segments, the olfactory bulbs (OB), the cerebrum (CB 1&2), the
brain stem (BS), cerebellum (CE), spinal cord (SP) and trigem-
inal nerves (TN) at 10 min after nasal administration of [3H]l-
DOPA hydrogel, the time point with the highest brain uptake ob-
served in the present study, by liquid scintillation analysis (Fig-
ure 5a). As shown in Figure 5b, [3H]l-DOPA was distributed over
the entire brain and the highest [3H]l-DOPA level was detected
in TN among the dissected tissues, containing more than 30%
of the total radioactivity detected in the brain. Direct transport
of molecules from the nasal cavity to the brain can occur along
the olfactory and/or trigeminal nerves, originating in the CB and
pons of the BS, respectively.[15b] For instance, olfactory transfer
for [3H]dopamine has been reported and [125I]insulin-like growth
factor-I undergoes both olfactory and trigeminal pathways to
reach brain and spinal cord following nasal administration.[32]
The current data suggest a combination of both pathways ac-
counts for the transport of [3H]l-DOPA hydrogel after nasal de-
livery and that the trigeminal route may dominate the transport.
In addition to studies referred to above,[28,31] early studies have
demonstrated that intranasal administration of l-DOPA methyl
ester (higher solubility) solution can increase the extracellular
dopamine levels in the ipsilateral neostriatum in rats.[33] It has
also been proved that intranasally applied l-DOPA, dispersed
in castor oil, can alleviate Parkinson’s symptoms using a rat
model of Parkinson’s disease.[34] A recent Phase 2a clinical trial
has explored the therapeutic potential for intranasal l-DOPA for
Parkinson’s disease by administration of a powder formulation of
l-DOPA using a specific nasal spray device (NCT03541356).[35]
The results of the present study demonstrate the genuine po-
tential of this supramolecular gel-mediated approach for the en-
hanced intranasal delivery of l-DOPAwith increased bioavailabil-
ity (higher uptake in the brain). Formulations such as this can
potentially be applied to other neurological drugs to treat a wider
range of neurodegenerative conditions.
3. Conclusions
In summary, we report a simple two-component supramolecular
hydrogel that has appropriate rheological performance and can
undergo rapid self-healing, making it suitable for use in nasal
drug delivery. The gel can be loaded with l-DOPA, our model
drug in this study, without disturbing the gel structure. l-DOPA
is largely mobile within the liquid-like phase of the gel and the
mobile l-DOPA undergoes release from the gel with rapid kinet-
ics. In vitro studies have demonstrated the cytocompatibility of
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Figure 5. Brain distribution of [3H]l-DOPA hydrogel at 10 min post intranasal administration. a) Dorsal view of the mouse brain and dissection guidance
of different brain segments, the olfactory bulbs (OB), the cerebrum (CB 1&2), the brain stem (BS), cerebellum (CE), spinal cord (SP), and trigeminal
nerves (TN). b) % of [3H]l-DOPA uptake in different brain segments. At the experimental end points, whole body perfusion with 0.9% saline was
performed and studied tissues were dissected and proceeded for liquid scintillation counting. Results are expressed as % uptake normalised to total
[3H]l-DOPA detected in these collected tissues. Data are expressed as mean ± SD, n = 3.
these gels. In vivo studies have indicated that the gel formula-
tion assists with retention in the nasal cavity, limits passage of
the drug into the GI tract and subsequent liver metabolism, and
enhances levels of blood and brain uptake. Specifically, the nasal
delivery gel achieved 4.1 timesmore brain uptake of l-DOPA and
2.1 times more l-DOPA in the blood 10 min after administration
than intravenous delivery of an equivalent dose. The gel formula-
tion was also significantly more effective than the administration
of a simple l-DOPA solution intranasally.
We therefore suggest that this gel may have potential in nasal
delivery, and that more widely, self-assembling gels with self-
healing characteristics based on low-molecular-weight systems
are a suitable low-cost formulation technology for this applica-
tion. The ability to rapidly achieve effective levels of drug in the
brain, avoiding first pass liver metabolism, suggests that this
supramolecular gel-mediated intranasal drug delivery approach
may have a great value in delivering a wide range of therapeu-
tics for treating different difficult-to-treat, debilitating, and costly
brain disorders such as brain malignancies, neurodegenerative
diseases, and psychiatric diseases. Future work would need to fo-
cus on measurement and optimization of the system in terms
of achieving therapeutic benefit whilst minimizing toxicity, a
fuller pharmacokinetic survey across multiple timepoints, devel-
opment for operation within nasal spray devices and the incor-
poration of other additives into these simple formulations to po-
tentially further enhance the delivery and half-life of the active
pharmaceutical ingredient.
4. Experimental Section
Full details of materials, methods, and additional data can be found in
Supporting Information.
Statistical Methods: For in vitro and in vivo experiments, data are pre-
sented as mean ± SD, where n denotes the number of repeats. Significant
differences were examined using one-way ANOVA using GraphPad Prism
8. p < 0.05 was considered statistically significant in all studies.
In Vivo Brain andOrgan Biodistribution Studies: All animal experiments
were performed in compliance with the UK Animals (Scientific Proce-
dures) Act 1986 and UK Home Office Code of Practice for the Housing
and Care of Animals Used in Scientific Procedures (Home Office 1989). In
vivo experimentation was adhered to the project license approved by the
King’s College London animal welfare and ethical review body (AWERB)
and UK Home Office (PBE6EB195).
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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